INTRODUCTION
Nonhealing wounds contribute over $50 billion dollars annually to the rising healthcare expenditures in the United States. 1 Increased prevalence rates in wounds failing to proceed through the normal repair process have been accompanied by a similar rise in the marketing of various advanced therapies aimed at the promotion of timely wound closure. 2 For over a century, scientific literature has reported the use of fresh human placental membranes (HPM) in the treatment of burns and wounds. [3] [4] [5] Advances in tissue preservation have led to the abundant commercialization of HPM, resulting in an expansive category of these products, each characterized by different compositions and properties. [6] [7] [8] [9] These point-of-care allografts range from decellularized products, which possess only the placental structural matrix, to viable cryopreserved products, which retain all placental membrane components in their native state. 8, 9 Published clinical data comparing patient outcomes associated with the use of different HPM products for wound treatment do not currently exist. Comparative effectiveness research (CER), in the form of nonrandomized cross-sectional studies using retrospective databases, is an organized approach to identifying which interventions from the same class of products work best once they are broadly applied in the clinical setting. 10 This is the first study to summarize the comparative clinical outcomes following the use of two different HPM products in the management of acute and chronic wounds at a single-center over a 25-month period.
METHODS
The rationale for this investigator initiated study was the lack of available CER between commercial placental products. Treatment with advanced therapies such as skin substitutes are initiated at this center once wounds have failed to demonstrate a response to standard of care (SOC) measures. The a priori specification of the research question focused on the clinical outcomes in two nonrandomized past patient cohorts receiving wound treatment that included either a viable intact cryopreserved human placental membrane (vCPM) (Grafix; Osiris Therapeutics, Inc., Columbia, MD), or a dehydrated human amnion/chorion membrane (dHACM) (EpiFix; MiMedx Group, Inc., Marietta, GA), as evidenced through a single-center electronic database.
The focus of the protocol-based analysis was the proportion of complete wound closure during the study time period. For the purposes of this study, closure was defined as Co-morbid conditions include, but are not limited to the following; diabetes, peripheral arterial disease, chronic venous insufficiency, chronic kidney disease, hypertension, end stage renal disease, hyperlipidemia, obesity, congestive heart failure, idiopathic neuropathy, tobacco abuse. Other wound types include the following; trauma, burn, pyoderma gangrenosum, polyneuropathic not related to diabetic etiology, dog bite, vasculitis. † vCPM, Grafix; dHACM, EpiFix: the preparation and clinical application of all vCPM and dHACM were performed according to the manufacturer's instructions and utilized in conjunction with consistent application of supportive SOC measures across both treatment groups. ‡ PAR, percentage area reduction; PVR, percentage volume reduction.
100% reepithelialization of the wound bed. Endpoints for additional analyses included: the proportion of wound closures that occurred by week 12; the number of grafts to achieve wound closure; and the percentage surface area reduction (PAR) and percentage volume reduction (PVR) for all nonclosed wounds. Institutional approvals were obtained prior to study initiation. De-identified data sets, consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), were collected from the electronic health record (EHR) wound management software.
Wound treatment involving dHACM at the hospital-based outpatient center began in February 2014, and occurred over a time period antecedent to that of institutional approval for use of vCPM in June 2015. Subject enrollment in the vCPM analysis was stopped once the number of vCPM-managed patients was proportionate to that of the dHACM group. Both subject groups, dHACM (n 5 39) and vCPM (n 540), represent distinct, consecutive sets of patients managed with either graft for the purposes of wound closure and do not reflect a subset of either population.
All male and female patients over 18 years of age with any body mass index (BMI) and health status, receiving at least one application of either vCPM or dHACM, with at least one follow-up measurement were eligible for analysis. In addition to the collection of baseline patient demographics, comorbid disease states were sourced from ICD-9 coding in the EHR. Pertinent conditions included, but were not limited to, diabetes, peripheral arterial disease, chronic venous insufficiency, chronic kidney disease, hypertension, end stage renal disease, hyperlipidemia, obesity, congestive heart failure, idiopathic neuropathy, and tobacco use.
This study evaluated all treated wounds, inclusive of all durations, sizes (cm 2 ), volumes (cm 3 ), etiologies, and locations. Data collection included wound etiology and anatomic location, wound duration prior to vCPM or dHACM initiation, baseline and serial wound dimensions (represented as length, width, and depth in centimeters), as well as standard-of-care (SOC) measures implemented with graft applications, including primary and secondary dressings, debridement, offloading, and compression. Wound classification was based on the primary etiological presentation and diagnosis, categorized as follows: diabetic foot ulcer (DFU); venous leg ulcer (VLU); arterial ulcer; pressure ulcer; surgical wound; or other, defined as none of the aforementioned etiologies.
All data were verified for accuracy and completion prior to the statistical analysis performed by an independent and treatment-blinded third-party contract research organization (CRO). Categorical variables were expressed as percentages while quantitative variables were expressed as mean and standard deviation (SD) and median values. Comparison of categorical variables were performed using the ChiSquare (v 2 ) test or Fisher's exact test. Satterthwaite approximation accounted for t-test sample variances, p-values of <0.05 were regarded as statistically significant. A Kaplan-Meier analysis was performed in order to evaluate the probability of 100% wound closure at 12 weeks (day 91). Data censoring for confounding variables included: measurements taken during the overlapping of adjunctive advanced treatments such as negative pressure wound therapy (NPWT) or hyperbaric oxygen therapy (HBOT) and measurements exceeding 6 weeks following the last graft application in all nonclosed wounds.
RESULTS
Demonstrated by the study analysis summarized in Table  1 , treatment cohorts were equal, as there were no statistical differences in the baseline patient characteristics, wound characteristics or etiological distribution of wound types between the two groups. Chronic wounds (>28-day duration) comprised 97.8% (45/46) of vCPM-treated wounds and 96.4% (53/55) of dHACM-treated wounds. DFUs constituted 15.2% of wounds in the vCPM group (n 5 7) and 20.0% in the dHACM group (n 5 11). Additional details for the DFUs are as follows for vCPM and dHACM, respectively: neuro-ischemic: 28.6% (2/7) and 9.1% (1/11); neuropathic: 71.4% (5/7) and 90.9% (10/11); plantar surface of the foot: 57.1% (4/7) and 45.5% (5/11); Wagner Grade 2 or 3: 85.7% (6/7) and 45.5% (5/11). There were no Wagner Grade 4 and 5 DFUs or DFUs with an underlying Charcot deformity treated in this study.
The proportion of wounds achieving complete wound closure was 63.0% (29/46) in the vCPM group compared with 18.2% (10/55) in the dHACM group (p < 0.0001) for all wound types combined. The odds ratio for complete closure for a vCPM-managed wound compared with dHACM was 7.50 (95% CI 2.84 -21.30). Individual analysis of wound closure based on etiology showed statistically significant outcomes between vCPM vs. dHACM in VLUs (70.0% vs. 7.1%, p 5 0.0024), surgical wounds (81.8% vs. 18.2%, p 5 0.009) and other wound types (83.3% vs. 28.6%, p 5 0.0449) ( Table  1) . These results are contributors to the difference in outcomes between the two groups. Ninety (90.0) percent of wound closures (vCPM: 26/29; dHACM: 9/10) occurred by week 12 of treatment. A Kaplan-Meier analysis calculated the probability of complete wound closure for week 12 (day 91) in both groups as 74.3% for vCPM (n 5 46) and 19.0% for dHACM (n 5 55) (p 5 0.0028) (Figure 1) .
The average size (area/volume) of wounds closed with vCPM was 9.4 cm 2 /10.3 cm 3 , which required an average of 2.7 graft applications over 59.7 days. The average size of wounds closed with dHACM was 2.1 cm 2 /0.5 cm 3 and required an average of 1.5 graft applications over 31.0 days. The difference in the number of graft applications and treatment durations for vCPM correlated with the statistically larger size of wounds closed in this group (p 5 0.0201).
Additional analyses included the changes in overall wound dimensions for nonclosed wounds, PAR and PVR were calculated as the differences between the baseline and final wound measurements after treatment. A mean 43.1% surface area reduction and a mean 39.6% volume reduction was demonstrated in the vCPM-managed wounds compared with a mean 72.6% increase in surface area and a mean 135.7% increase in volume for dHACM-managed wounds ( Table 1 ). The p-values of 0.0382 for PAR and 0.0782 for PVR show that changes in wound size are marginally different between the two groups. For nonclosed DFUs, a mean PAR of 60.4% vs. 18.8% (p 5 0.345) and a mean PVR of 52.6% vs. 6.2% (p 5 0.388) were observed in vCPM and dHACM, respectively (data not shown). There were no statistical differences in the number of graft applications and treatment duration that resulted in final mean PAR/PVR values PAR/PVR values for nonclosed wounds between the two groups ( 11, 12 When used in conjunction with SOC, vCPM resulted in a higher rate of complete closure than SOC alone (62.0% vs. 21.0%, p < 0.0001) by week 12.
11 In a prospective singlecenter trial Toursavadkohi et al. demonstrated a 6-week closure rate of 60.0% for chronic VLUs treated with vCPM in conjunction with multilayer compression compared with 20.0% in those treated with multilayer compression alone (p < 0.05). 13 In a retrospective analysis of chronic wound management with vCPM, Regulski et al. reported closure rates of 85.2% for DFUs, 67.6% for VLUs, 83.3% for other wounds with an overall 76.1% for all wounds combined by week 12.
14 Despite the differences in design, all studies show similar clinical outcomes for vCPM.
For dHACM, the prospective, single-center, RCT published by Zelen et al. reported 6-week closure rates in DFU (n 5 13) treated with dHACM compared with those treated with Silvasorb gel and Aquacel AG (n 5 12) (92.0% vs. 8.0%, p < 0.001). 15 Similar DFU wound closure rates at 12 weeks were reported in other dHACM RCTs, also conducted by Zelen. 16, 17 In contrast, a large volume retrospective EHR database analysis conducted by Kirsner et al. found that only 28.0% of dHACM-treated DFU resulted in closure by week 12. 18 In a 4-week multi-center RCT, Serena et al. (2014) described VLU closure rates of 11.3% (6/53) in the dHACM and multilayer compression group compared with 12.9% closure (4/31) with multilayer compression alone. 19 A follow up retrospective study examining the nonclosed wounds from the 4-week RCT correlated 80.0% VLU closure in the dHACM group at week 24 to the 40% of wound area reduction reported by the RCT at 4-weeks. 19, 20 However, a significant limitation to the outcomes reported by Serena et al. (2015) was the allowance of other adjunct advanced therapies after completing the initial 4-week RCT, and therefore an 80.0% wound closure rate cannot be attributed solely to dHACM. 20 Effectiveness reviews such as the one presented in this report should assist with selection of advanced therapies while justifying the product cost to the facility and healthcare system at large. Although treatment cohorts in the study were well balanced as demonstrated by the lack of statistically significant differences for key patient and wound characteristics between the two treatment groups, the authors recognize that the retrospective and nonrandomized nature of this single-center study present significant limitations. High quality evidence for non-DFU wound types does not currently exist in the literature for vCPM and dHACM; however, the objective of this present
